2-Pivaloylimidazol | 61985-30-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Pivaloylimidazol
• 英文别名: 1-(1H-imidazol-2-yl)-2,2-dimethyl-propan-1-one；1-Propanone, 1-(1H-imidazol-2-yl)-2,2-dimethyl-；1-(1H-imidazol-2-yl)-2,2-dimethylpropan-1-one
• CAS: 61985-30-6
• 化学式: C₈H₁₂N₂O
• 分子量: 152.196
• InChiKey: MDSTUPSOASFSDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(1-methoxymethyl-1H-imidazol-2-yl)-2,2-dimethyl-propan-1-one 、 盐酸 以61%的产率得到
  参考文献：
  名称：

  REGEL E., J. LIEBIGS ANN CHEM. , 1977, NO. 1, 159-168

  摘要：

  DOI：

文献信息

• Crystalline sugar compositions and method of making
  申请人：Major Michael

  公开号：US20060293250A1

  公开（公告）日：2006-12-28

  Described are novel crystalline pivaloyl furanoses and methods of crystallizing the pivaloyl furanoses. These compounds are useful as intermediates in the synthesis of compounds such as the deoxyjirimycins and nojirimycins and are particularly useful as intermediates for production on a multi-kg scale. Particular crystalline compounds include 1,2,3,6-tetrapivaloyl-α-D-galactofuranose, 1,2,3,6-tetrapivaloyl-α-L-altrofuranose, and 5-azido-5-deoxy-1,2,3,6-tetrapivaloyl-α-D-galactofuranose.

  本文描述了新型结晶式戊酰基呋喃糖以及结晶戊酰基呋喃糖的方法。这些化合物可用作合成脱氧吉利霉素和诺吉霉素等化合物的中间体，并且在多千克级别的生产中特别有用。特定的结晶化合物包括1,2,3,6-四戊酰基-α-D-半乳糖呋喃糖、1,2,3,6-四戊酰基-α-L-阿尔卓糖呋喃糖和5-叠氮基-5-脱氧-1,2,3,6-四戊酰基-α-D-半乳糖呋喃糖。
• CRYSTALLINE SUGAR COMPOSITIONS AND METHOD OF MAKING
  申请人：Amicus Therapeutics, Inc.

  公开号：EP1888612A1

  公开（公告）日：2008-02-20
• 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators
  申请人：Kaufman L. Mildred

  公开号：US20070054933A1

  公开（公告）日：2007-03-08

  Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
• CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
  申请人：NEUPHARMA, INC.

  公开号：US20170050936A1

  公开（公告）日：2017-02-23

  Chemical entities that are effective as kinase inhibitors, pharmaceutical compositions and methods of treatment are disclosed. The chemical entities disclosed specifically inhibit signal transduction and cellular proliferation by modulating the activity of protein kinases to regulate and modulate abnormal or inappropriate cell proliferation, differentiation, or metabolism. The compounds include a pyrido[3,2-d]pyrimidine scaffold substituted with aromatic and heteroaromatic moieties.
• SMALL MOLECULE MODULATORS OF PAR2 AND USES THEREOF
  申请人：Arizona Board of Regents on Behalf of the University of Arizona

  公开号：US20210107909A1

  公开（公告）日：2021-04-15

  This invention is in the field of medicinal pharmacology. In particular, the invention relates to a new class of small-molecules having a pyrazino-pyrimidine-dione (or related) structure which function as modulators (activators, inhibitors) of protease activated receptor type 2 (PAR2), and their use as therapeutics for the treatment of conditions involving PAR2 activity (e.g., asthma, chronic pain, cancer and/or vascular disorders).